Indication: Treatment of exocrine pancreatic insufficiency in children and adults. Exocrine pancreatic insufficiency is common in (but not limited to) cystic fibrosis, chronic pancreatitis, post-pancreatectomy, post-gastrectomy, pancreatic cancer, and post-gastric bypass reconstruction (such as Billroth II subtotal gastrectomy)

Indication: It is mainly used to treat various infections caused by various sensitive bacteria, especially staphylococci, such as osteomyelitis, sepsis, endocarditis, recurrent cystic fibrosis, pneumonia, skin and soft tissue infections, surgical and traumatic infections, etc.

Indication: Vaccination target: Influenza split vaccine is recommended for adults and children over 6 months old to prevent influenza. This product is especially recommended for the following groups: - People over 60 years old. - People with cardiovascular diseases, metabolic diseases (diabetes), cystic fibrosis, chronic respiratory diseases and chronic renal insufficiency. - Patients with congenital or acquired immunodeficiency or deficiency. - People living in nursing homes or sanatoriums. This product is also recommended for people whose occupational risk of infection increases, such as medical staff.

Indication: This product can be used for nutritional support in the following clinical situations: chronic obstructive pulmonary disease, respiratory failure, ventilator dependence, and pulmonary manifestations of cystic fibrosis.

Indication: It is mainly used to treat various infections caused by various sensitive bacteria, especially staphylococci, such as osteomyelitis, sepsis, endocarditis, recurrent cystic fibrosis, pneumonia, skin and soft tissue infections, surgical and traumatic infections.

Indication: ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in patients 6 years of age and older who have at least one F508del CFTR Table 5 [see Clinical Pharmacology (12. 1) If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one indicated mutation. ALYFTREK is a combination of deutivacaftor, a CFTR potentiator, tezacaftor, and vanzacaftor indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del CFTR 1 12. 1 If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one indicated mutation.

Indication: TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del CFTR CFTR Table 6 [see Clinical Pharmacology (12. 1) If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one indicated mutation [see Clinical Pharmacology (12. 1) TRIKAFTA is a combination of ivacaftor, a CFTR potentiator, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del CFTR CFTR If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one indicated mutation.

Indication: ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in patients 6 years of age and older who have at least one F508del CFTR Table 5 [see Clinical Pharmacology (12. 1) If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one indicated mutation. ALYFTREK is a combination of deutivacaftor, a CFTR potentiator, tezacaftor, and vanzacaftor indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del CFTR 1 12. 1 If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one indicated mutation.

Indication: TOBI Podhaler is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 Burkholderia cepacia [see Clinical Studies (14) TOBI Podhaler is an aminoglycoside antibacterial indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 Burkholderia cepacia 1.

Indication: Tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 Burkholderia cepacia [see Clinical Studies ( 14 Tobramycin inhalation solution is an aminoglycoside antibacterial indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa 1 Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV1) 75% predicted, or patients colonized with Burkholderia cepacia.